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Abstract
Aims In acute heart failure (AHF), changes of venous haemoglobin (Hb) concentrations, haematocrit (Hct), and estimated
plasma volume (ePV) have been proposed as surrogates of decongestion. These estimates are based on the theoretical
assumptions that changes of Hb concentrations and Hct are driven by the intravascular volume status and that the intravas-
cular Hb pool remains stable. The objective of this study was to assess the relationship of changes of measured plasma volume
(mPV) with changes of Hb, Hct, and ePV in AHF.
Methods and results We studied 36 AHF patients, who received two sequential assessments of mPV, measured red cell
volume (mRCV) and measured total blood volume (mTBV) (48 h apart), during the course of diuretic therapy using a novel
visible fluorescent injectate (VFI) technique based on the indicator dilution principle. Changes of ePV were calculated based
on the Kaplan–Hakim or Strauss formula. AHF patients receiving diuretics (median intravenous furosemide equivalent
160 mg/48 h) displayed a wide range of changes of mPV (25.4% to +37.0%). Changes in mPV were not significantly corre-
lated with changes of Hb concentration [Pearson’s r (r) = 0.241, P = 0.157], Hct (r = 0.307, P = 0.069), ePVKaplan–Hakim
(r = 0.228, P = 0.182), or ePVStrauss (r = 0.237, P = 0.163). In contrast to theoretical assumptions, changes of mTBV were poorly
correlated with changes of Hb concentrations and some patients displayed unanticipated variability of mRCV, suggesting an
unstable intravascular red cell pool.
Conclusions Changes of Hb or Hct were not reflective of directly measured changes of intravascular volume status in AHF
patients. Basing clinical assessment of decongestion on changes of Hb or Hct may misguide clinical decision-making on an
individual patient level.
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Introduction
More than 90% of hospitalizations in heart failure (HF)
patients are due to signs and symptoms of fluid overload,
and congestion remains the primary challenge in acute HF
(AHF).1 Monitoring congestion is important in all stages of
HF management: in the outpatient setting to prevent decom-
pensation, in the emergency department to identify AHF, and
during the course of decongestive treatment to guide therapy
and to identify patients nearing discharge from an AHF
hospitalization.
The integrative assessment of congestion and volume sta-
tus is based on clinical congestion scores, biomarkers, and im-
aging tools.2 Clinical assessment, containing, for example,
change in body weight, oedema grade, and dyspnoea grade,
is typically performed repeatedly within routine care, but
evaluation is error prone or examiner dependent and re-
quires clinical expertise. Clinical scores are time consuming
and limited in detecting mild congestion.
It has been suggested that changes in the readily available
parameters haemoglobin (Hb) concentration and haematocrit
(Hct) may provide surrogates of effective decongestion and,
hence, may be helpful in evaluating the effects of therapies
in AHF patients.2,3 This suggestion is based on several large
retrospective post hoc studies that have indicated an associ-
ation between haemoconcentration (defined by increasing
Hb concentrations or Hcts) and beneficial clinical outcomes
in patients hospitalized for AHF.4–8
Formula-based estimates of absolute plasma volume (PV)
using the Kaplan–Hakim formula9 are based on Hct, sex,
and body weight. Several studies have indicated a moderate
to good correlation of measured plasma volume (mPV) and
estimated plasma volume (ePV) by Kaplan–Hakim.10,11 An
estimated percentage change in plasma volume (%ΔePV) be-
tween two time points can be obtained by sequentially apply-
ing the Kaplan–Hakim formula or by using the Strauss
formula, which considers changes of Hct and Hb concentra-
tions (Supporting Information, Figure S1).12 Similar to the
outcome studies above, an increasing ePV based on the
Strauss formula has been associated with unfavourable
outcomes in AHF patients,13,14 while a decreasing Strauss-
based ePV at hospital discharge was associated with
decreased AHF-related readmissions and mortality.15
Nevertheless, it is unclear whether changes of Hb concen-
tration, Hct, and ePV based on the Kaplan–Hakim or Strauss
formula have clinical benefit in guiding therapy on an individ-
ual patient level, because prospective clinical studies are
missing. In addition, changes of Hb concentration and Hct
have never been tested against direct mPV in AHF patients.
Definitions of haemoconcentration and Strauss’ formula as-
sume that changes in Hb concentrations over time are
inversely proportional to changes of intravascular total blood
volume (TBV). This may be true if the total intravascular Hb
mass is stable and evenly distributed in different vascular
beds. An additional theoretic assumption that has not been
validated is that changes in Hct over time reflect the changes
in the ratio of red cell volume (RCV) to TBV.16 However, each
of these assumptions may be violated in AHF patients, who
frequently experience blood losses or receive blood transfu-
sions during hospitalization, events that will alter RCV, Hct,
and Hb concentrations independently of changes in PV. In ad-
dition, redistribution of red blood cells between the central
and the splanchnic circulations may occur in AHF, which
may induce dynamic changes of peripheral venous Hb con-
centrations and Hct independent of changes in TBV.17
In this study, we determined changes of mPV in AHF pa-
tients during 48 h of decongestive therapy based on the indi-
cator dilution principle using a novel intravenously injected
fluorescence dye labelled dextran. This allowed us to com-
pare Hb concentration changes, Hct changes, and ePV
changes with directly measured changes of PV. In addition,
we were able to investigate whether theoretical assumptions
underlying Hb-based and Hct-based definitions of ‘conges-
tion’ and ‘decongestion’ and Strauss’ formula-based PV
estimates may be violated in AHF patients. These data repre-
sent the first time these associations have been tested.
Methods
Study cohort
The data presented are results of a pre-specified secondary
analysis from a prospective phase 2b study that enrolled
hospitalized patients who were treated for AHF using decon-
gestive therapy (study identifier, EmPaKt-CHF; EudraCT num-
ber, 2018-002638-18, https://clinicaltrials.gov/ct2/show/
NCT03808948), which was performed between January and
July 2019 at the nephrology and two cardiology departments
of Charité – Universitätsmedizin Berlin and at the cardiology
department of Kerckhoff Klinik Bad Nauheim.18 Eligible par-
ticipants were aged ≥18 years and had a diagnosis of AHF
and were undergoing either intravenous or oral diuretic
treatment. Evidence of AHF was based on presence of ≥1
symptom (dyspnoea, orthopnoea, or oedema) and ≥1 sign
(rales, peripheral oedema, ascites, or pulmonary vascular
congestion on chest radiography).19 Exclusion criteria in-
cluded pregnancy, acute onset of myocardial infarction,
unstable angina pectoris, new onset of atrial fibrillation, re-
quirement of intravenous vasodilators or inotropic agents,
acute or chronic need for kidney replacement therapy, signif-
icant non-cardiac diseases (e.g. malignancies and neurode-
generative diseases), severe infections, and internal
bleeding. Nonsterile participants agreed to use effective
methods of contraception.
All 50 study subjects received a quantitative measure of PV
at enrolment. A subset of 36 patients with a second PV
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measurement 48 h after enrolment was analysed in this
study, and changes in mPV were compared with changes of
formula-based estimates of PV. Treating physicians were
blinded to the directly mPV values.
Participants gave written informed consent. Data
were handled in respect of patient anonymity and confi-
dentiality. The study protocol was approved by the regional
ethics board and conducted in accordance with the Declara-
tion of Helsinki guidelines. The authors had full access
to the data and take full responsibility for its integrity. All
authors have read and agreed to the manuscript as written.
Study-related parameters
Plasma volume was measured after enrolment (Day 1) and
48 ± 5 h after the first measurement (Day 3). mPV was deter-
mined using visible fluorescent injectate (VFI) (FAST Biomed-
ical, Indianapolis) as previously described.20 VFI consists of
12 mg of a 150 kDa carboxymethylated dextran, conjugated
to a rhodamine dye (FD003) that allows repeat PV measure-
ments for at least 6 h after injection, and 35 mg of a 5 kDa
carboxymethylated dextran, conjugated to fluorescein
(FD001), that is freely filtered by the kidney. The VFI tech-
nique can measure both PV and glomerular filtration rate
(GFR) in a clinically actionable fashion.20,21 The large PV fluo-
rescent marker has a half-life of nearly 100 h in the vascular
system, and the small GFR marker’s clearance is determined
by the subject’s GFR.
A volume of 3.0 mL was injected intravenously over 30 s.
Blood samples of 3 mL were collected right before and 15,
30, 60, and 180 min after injection. Blood plasma was run
on a validated BioAnalytical HPLC assay at Covance Laborato-
ries in Salt Lake City, Utah. PV was determined using the av-
erage FD003 concentrations of the early 15 min and the
60 min time point using the indicator dilution principle after
distribution in the vascular system. Functionality and safety
of the VFI technique, including stable plasma concentrations
of the PV marker FD003 over the 15 and 60 min time points,
are reported elsewhere.18
Venous blood (3 mL) was drawn to determine Hb concen-
tration and Hct before injection of the fluorescent tracer to
calculate ePV according to the Strauss formula.12 Hct was de-
termined by multiplying the red cell count by the mean cell
volume (Labor Berlin, Germany). Hb concentration was mea-
sured photometrically (Labor Berlin). Measured red cell vol-
ume (mRCV) was calculated from mPV and total body
haematocrit (TBHct22):
mRCV ¼ mPV
1  TBHctð Þ  mPV
Measured total blood volume (mTBV) was calculated from
mPV and TBHct22:
mTBV ¼ mPV
1  TBHctð Þ
Estimated PV was calculated using the Kaplan–Hakim
formula9:
ePVKaplan  Hakim ¼ 1  haematocritð Þ  aþ b weightin kgð Þ½ 
a = 1530 in males and 864 in females; b = 41 in males and
47.9 in females.
Figure 1 Study flow chart. PV, plasma volume; VFI, visible fluorescent injectate.
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Estimated 48 h change of PV was calculated using percent-
age change of the Kaplan–Hakim formula-derived estimates
(%ΔePVKaplan–Hakim):
%ΔePVKaplanHakim ¼ ePVKaplanHakim Day 3ð Þ  ePVKaplanHakim Day 1ð Þ
ePVKaplan  Hakim Day 1ð Þ 100
Estimated 48 h change of PV was also calculated using the
Strauss formula (%ΔePVStrauss)
12 where Day 1 designates
enrolment day and Day 3 the day of second PV measurement
48 h later:
%ΔePVStrauss ¼ 100 Hb Day 1ð Þ
Hb Day 3ð Þ
 
 1  Hct Day 3ð Þ
1  Hct Day 1ð Þ
  
 100




Age (years) 72.6 ± 13.1
Male 27 (75)
Caucasian 35 (97.2)
Clinical data at enrolment
Weight (kg) 89.9 ± 23.7
BMI (kg/m2) 30.1 ± 6
BSA (m2)a 2.0 ± 0.31
Systolic blood pressure (mmHg) 126.7 ± 24.8
Diastolic blood pressure (mmHg) 72.1 ± 15.4
Heart rate (b.p.m.) 75.2 ± 13.5
NYHA Class II 4 (11.1)
NYHA Class III–IV 32 (88.9)





Acute decompensation of chronic heart
failure
35 (97.2)
De novo AHF 1 (2.8)
Clinical presentation
Acute decompensated heart failure 23 (63.9)
Acute pulmonary oedema 11 (30.6)
Isolated right ventricular failure 2 (5.6)
Factors triggering AHF
Ischaemia 3 (8.3)
Valvular disease 6 (16.6)
Worsening of pulmonary disease 3 (8.3)
Infection 2 (5.6)
Non-adherence of salt/fluid intake or
medication
7 (19.4)
Uncontrolled arrhythmia 3 (8.3)
Uncontrolled hypertension 2 (5.6)
Anaemia 1 (2.8)




Coronary artery disease 25 (69.4)
Hypertension 33 (91.7)
CKD Stage 1–2 15 (41.7)
CKD Stage ≥3 21 (58.3)
Medication before hospitalization
Oral loop diuretic 29 (80.6)
RAASI 27 (75)
Thiazide diuretic 4 (11.1)
Aldosterone antagonist 14 (38.9)
Beta-blocker 28 (77.8)
Medication at enrolment
Intravenous loop diuretic 30 (83)
Oral loop diuretic only 6 (17)
RAASI 27 (75)
Thiazide diuretic 5 (13.9)
Aldosterone antagonist 15 (39.5)
Beta-blocker 29 (76.3)
Intravenous furosemide equivalent dose
at enrolment day (mg)c
80 (60–135)
Laboratory values at enrolment
eGFR CKD EPISCr (mL/min/1.73 m
2) 39.3 ± 17.4
NT-proBNP (ng/L)b 3895 (1822–82 93)
Hct (%) 34.9 ± 6.9
Hb (g/dL) 11.6 ± 2.3
Volume measures and estimates
mTBV (L) 5.1 ± 1.3
mRCV (L) 1.6 ± 0.5
mPV (L) 3.5 ± 0.9
AHF, acute heart failure; BMI, body mass index; CKD, chronic kid-
ney disease; eGFR, estimated glomerular filtration rate; Hb,
haemoglobin; Hct, haematocrit; HFmrEF, heart failure with
mid-range ejection fraction; HFpEF, heart failure with preserved
ejection fraction; HFrEF, heart failure with reduced ejection frac-
tion; LVEF, left ventricular ejection fraction; mPV, measured plasma
volume; mRCV, measured red cell volume; mTBV, measured total
blood volume; NT-proBNP, N-terminal pro-brain natriuretic pep-
tide; NYHA, New York Heart Association; RAASI, renin-angioten-
sin-aldosterone system inhibitors.
Data are presented as median and interquartile range or number
and percentage, as appropriate. Data are rounded to one decimal
place except NT-proBNP (next integer).
aBSA = body surface area according to Dubois et al.30
bMissing data: n = 1.
cFurosemide equivalent dose: 20 mg furosemide i.v. ≙ 40 mg furo-
semide p.o. ≙ 20 mg torasemide p.o.
Figure 2 Correlation of mPV and the corresponding ePV based on the
Kaplan–Hakim formula. Pearson’s correlation coefficient (r) and the asso-
ciated P-value are shown. ePV, estimated plasma volume; mPV, mea-
sured plasma volume.
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Statistical analyses
Descriptive analyses were performed by reporting the
quantiles of the empirical distributions of the respective
variables, for example, mean and standard deviation for con-
tinuous data, median and interquartile range (IQR) for
skewed distributed data, and frequencies with percentages
for categorical variables. The Wilcoxon test was used to com-
pare dependent samples for continuous variables.
Correlations between percentage changes in mPV and ePV
were determined using Pearson’s correlation coefficients.
The Bland–Altman plots were used to analyse the agreement
of percentage changes in mPV and percentage changes in
ePV. Statistical analyses were performed using SPSS (Chicago)
Version 25 and GraphPad Prism Version 8. All reported
P-values are two-tailed. Due to the exploratory character of
the study, all reported results and P-values have to be consid-
ered as non-confirmatory.
Figure 3 Frequency distribution of percentage changes of (A) mPV, (B) mRCV, and (C) mTBV within 48 h of diuretic treatment. mPV, measured plasma
volume; mRCV, measured red cell volume; mTBV, measured total blood volume.
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Results
Figure 1 represents a flow chart of the inclusion of 36 AHF
patients who had two sequential PV measurements during
the course of decongestive therapy. The first measurement
was performed 2 days (median; IQR 1–3 days) after hospital
admission (Day 1), and the second measurement was
performed 48 ± 5 h later (Day 3). The administered intrave-
nous furosemide equivalent dose was 80 mg (median; IQR
60–135 mg) on Day 1 and 70 mg (median; IQR
32.5–120 mg) on Day 2. Cumulative median 48 h dose was
160 mg/48 h (IQR 102.5 to 240 mg/48 h).
The demographics and clinical characteristics for the study
cohort of 36 patients are shown in Table 1. Most of the pa-
tients were male (75%) and Caucasian (97.2%). The mean
age was 72.6 (±13.1) years. The majority of patients had heart
failure with a preserved ejection fraction (HFpEF, 61.1%) and
pre-existing chronic kidney disease (CKD) Stage 3 or higher
(58.3%).
First, we evaluated the correlation and agreement of a
Kaplan–Hakim formula-based estimate of absolute PV (ePV-
Kaplan–Hakim) with mPV on enrolment. While we found a signif-
icant positive correlation between ePVKaplan–Hakim and mPV
(r = 0.75, P < 0.0001; Figure 2), the Bland–Altman plots re-
vealed relatively wide limits of agreement between
ePVKaplan–Hakim and mPV (1345 to +1022 mL) and a bias of
161 mL, indicating that ePVKaplan–Hakim slightly
underestimated mPV (Supporting Information, Figure S2).
The cohort demonstrated a wide spectrum of changes of
mPV, mRCV, and mTBV during 48 h of diuretic therapy
(Figure 3). Changes of mPV ranged from 25.4% to +37.0%,
changes of mRCV ranged from 30.9% to +38.1%, and
changes of mTBV ranged from 25.3% to +34.0%. Most pa-
tients displayed decreases of mPV and mTBV during the
48 h of decongestive therapy. In contrast, fewer patients
displayed decreases of mRCV and the distribution of changes
of mRCV was wide, suggesting an unanticipated variability of
mRCV in some patients.
We next investigated average changes in mPV, mRCV,
mTBV, Hb concentration, Hct, and body weight during 48 h
of decongestive therapy on a population scale (Table 2).
While body weight decreased significantly from Day 1 to
Day 3 (89.9 ± 23.7 kg vs. 88.8 ± 22.7 kg, P = 0.001), none of
the other parameters displayed significant population-wide
differences during the time course of decongestive therapy.
This was consistent with the wide ranges of changes de-
scribed above. In agreement with a previous study,23 we
observed no apparent relationship between the amount of
change in PV and the change in body weight (Supporting
Information, Figure S3).
We next compared changes in mPV with changes in Hb
concentrations, in Hct, and in ePV (based on the Kaplan–
Hakim and Strauss formula) during the 48 h study period.
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no significant correlation with changes in Hb concentrations
(r = 0.241, P = 0.157), changes in Hct (r = 0.307,
P = 0.069), changes in ePVStrauss (r = 0.237, P = 0.163), or
changes in ePVKaplan–Hakim (r = 0.228, P = 0.182) (Figure 4).
The Bland–Altman plots of Δ%ePV and Δ%mPV showed
wide limits of agreement (from 27.4% to +27.9% for the
Kaplan–Hakim and from 32.8% to +35.4% for the Strauss
formula; Supporting Information, Figure S4), confirming the
poor agreement between formula-derived estimated changes
and actual measured changes in PV. The accuracies of the
Kaplan–Hakim and Strauss formula in identifying a percent-
age change of ePV that was within ±10 percentage points
of the mPV change were only 50%, respectively.
We next aimed to obtain insights into the causes for these
limited associations of ePV estimates (Strauss’ formula) with
actual changes of PV. We performed correlation analyses
and found that the percentage changes of Hb concentrations
and percentage changes of measured TBV did not correlate
(r = 0.007, P = 0.967; Figure 5). This indicated that a key as-
sumption underlying Strauss’ formula, namely, the negative
correlation of Hb concentration changes and TBV changes,
was not fulfilled in AHF patients.
We found that 19 patients had a relatively stable RCV
(change of RCV less than ±10%). In these patients, the Strauss
formula performed well, providing a significant and positive
correlation of ePV with changes of mPV (r = 0.779,
P < 0.0001; Figure 6A). In contrast, 17 patients showed un-
stable RCV (change of RCV more than ±10%). In these pa-
tients, ePV displayed no correlation with actual changes of
mPV (r = 0.089, P = 0.734; Figure 6B).
Strauss’ formula is also based on the assumption that PV
and RCV undergo changes of the same directionality; that
is, an increase of PV would be accompanied by an increase
of RCV and vice versa. We therefore examined the associa-
tions of mPV and mRCV in our cohort. While percentage
changes of mPV and percentage changes of mRCV displayed
a positive correlation on a population level (r = 0.62,
P < 0.0001), individual patients displayed substantial devia-
tions from expected changes of mRCV (Figure 7A and 7B).
In search of potential explanation of these changes, we found
that three patients with substantial decreases in RCV had
clinical evidence of bleeding between the two PV measure-
ments whereas one patient with a substantial increase in
RCV had received red blood cell transfusions between the
two PV measurements. Nevertheless, in the majority of cases
of instable RCV, no clinical explanation was apparent from
the available data.
Discussion
This study demonstrates that, in AHF patients undergoing de-
congestive therapy, (i) changes of Hb concentration or Hct
correlate poorly with changes of mPV and (ii) the Kaplan–
Hakim and Strauss formula-based estimates of changes in
PV perform poorly in identifying actual changes of PV. Al-
though the Kaplan–Hakim formula provides an acceptable
Figure 4 Correlation of 48 h percentage change (%Δ) of mPV and the corresponding %Δ of Hb concentrations (A), %Δ of Hct (B), and %Δ of ePV based
on the Kaplan–Hakim (C) and Strauss formula (D). Pearson’s correlation coefficient (r) and the associated P-value are shown. ePV, estimated plasma
volume; Hb, haemoglobin; Hct, haematocrit; mPV, measured plasma volume.
Figure 5 The assumption of an inverse relationship of Hb changes and
TBV changes is violated in acute heart failure patients. Correlation of
48 h percentage change (%Δ) of TBV and percentage change of Hb concen-
tration. Pearson’s correlation coefficient (r) and the associated P-value are
shown. Hb, haemoglobin; mTBV, measured total blood volume.
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population-based estimation of mPV, its ability to estimate
individual 48 h changes in PV is poor. Utilization of Hb con-
centration, Hct, and Strauss’ formula in AHF patients is based
on assumptions of a stable intravascular Hb pool and of con-
cordant changes of PV and RCV. Under these assumptions,
changes in Hb concentration would be inversely proportional
to changes in TBV. However, in our study, no correlation was
found between changes in Hb concentration and changes in
TBV. Additionally, changes of RCV were frequently discordant
from changes of PV. This indicates that key assumptions
underlying Strauss’ equation are frequently violated in AHF
patients undergoing decongestive therapy. This may be re-
lated to several factors, including blood transfusions, blood
losses, or redistribution of red blood cells to and from remote
vascular beds (e.g. splanchnic circulation) during the course
of therapy of these hospitalized patients.
Figure 6 Impact of RCV stability on Strauss’ performance. (A) Correlation of percentage change of ePVStrauss and mPV in patients with mRCV change
within ±10%, n = 19, r = 0.779, P < 0.0001. (B) Correlation of percentage change of ePVStrauss and mPV in patients with mRCV change > +10% and
< 10%, n = 17, r = 0.089, P = 0.734. Pearson’s correlation coefficient (r) and the associated P-value are shown. ePV, estimated plasma volume;
mPV, measured plasma volume; mRCV, measured red cell volume.
Figure 7 Relationships of PV and RCV in patients with acute heart failure. (A) Percentage changes of mPV and mRCV are shown in individual patients.
Patients with decreasing PV are presented on the left, and patients with increasing PV on the right. *Patient received blood transfusion. †Patients with
clinical evidence of bleeding event. (B) Correlation of percentage changes of PV and percentage changes of RCV. Pearson’s correlation coefficient (r)
and the associated P-value are shown. Note the marked discordance of changes in PV and changes in RCV in some patients. mPV, measured plasma
volume; mRCV, measured red cell volume.
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Our findings are of importance when it comes to interpret-
ing changes of Hct, Hb concentrations, and ePV in AHF pa-
tients. Previous studies have found that increases of Hct or
Hb concentrations and decreases of ePV were associated
with better outcomes in AHF patients.4,6,7,13,24,25 This was
interpreted as evidence of a beneficial effect of aggressive
decongestion, but our study shows that caution should be ap-
plied when making such inferences, because changes of Hb
concentrations, Hct, estimates of PV, and changes of mPV
were frequently uncoupled in AHF patients. Therefore, it is
possible that increases of Hb concentrations or Hct during
AHF therapy may be driven by factors unrelated to changes
in PV. For instance, adverse outcomes in patients with in-
creasing ePV (or decreasing levels of Hct or Hb) may be re-
lated to the prognostic implications of worsening anaemia
rather than hypervolaemia.26
Consistent with our observations, Fudim and Miller re-
ported that the %ΔePVStrauss from hospital admission to dis-
charge in 40 chronic HF patients displayed a weak
association with measured changes of PV assessed with an in-
dicator dilution technique that uses radiolabelled albumin.11
While changes of RCV and TBV were not reported in that
study, the authors found that, unexpectedly, changes in ve-
nous Hb concentrations did not display a negative correlation
with quantitative changes in PV. Similar to our findings, Miller
and Mullan reported a wide range of RCV change between
admission and discharge in patients hospitalized for symp-
tomatic decompensation of chronic HF.23 In our study, we
found clinical explanations for RCV shifts (bleeding and red
blood cell transfusions) in a minority of cases. The remaining
observed disproportionate increases of RCV could be ex-
plained by recruitment of red blood cells from the spleen or
splanchnic circulation.27,28 In contrast, the observed de-
creases in RCV that sometimes exceeded the decreases of
PV may be explained by re-sequestration of red cells during
stabilization in response to decongestive treatment. Further-
more, changes of RCV may be related to repeated phlebot-
omy or impaired haematopoiesis due to decreased
erythropoietin production or abnormal response to erythro-
poietin associated with cardiac dysfunction.29 Taken to-
gether, these data suggest that subsets of AHF patients
display an unstable red blood cell pool, which leads to
PV-independent alterations of Hb concentrations and Hct
over time that contribute to the weak performance of ePV.
We observed a significant decrease in mean body weight
during diuretic therapy. In contrast, TBV and PV were in-
creasing in many patients. These observations are consis-
tent with those of Miller and Mullan23 and suggest that
mobilization of expanded interstitial fluid into the intravas-
cular space contributes to PV expansion and identifies the
interstitial space as the major source of fluid loss during
decongestion.
Finally, the use of a novel fluorescent marker technique,
with a rapid clinically actionable readout, will allow for quan-
titative evaluation of PV changes and adjustment of diuretic
therapy based on objective data not subjective evaluation
as is presently used. The technique also offers the ability
for repeat measurements over at least 6 h allowing the clini-
cian insight into clinical therapeutic decisions within this
timeframe.
Strengths and limitations
Our study is the first study to investigate measured changes
of PV, RCV, and TBV in AHF patients undergoing decongestive
therapy. The study is limited by a relatively small sample size
of 36 patients. In this study, we defined broad inclusion
criteria to represent patients with different types of HF (in-
cluding patients with preserved and reduced ejection frac-
tions) and a wide range of kidney function. While this
represents a strength of our study in terms of generalizability,
future studies will be needed to define specific subsets of
AHF patients who may benefit from direct measurement of
PV. Due to a short observation period, no long-term out-
comes are available for this study.
Conclusions
Using a quantitative rapidly actionable measurement of PV,
changes in intravascular mPV were not adequately reflected
by changes of Hb concentrations, Hct, or changes in the
Kaplan–Hakim or Strauss formula-derived ePV in AHF pa-
tients. The mechanisms responsible for these discrepancies
in AHF patients include an unstable intravascular red blood
cell pool and uncoupling of changes of PV and RCV in a subset
of patients. Our data suggest that changes of Hct, changes of
Hb concentrations, and changes of ePV are of limited value in
guiding decongestive therapy in AHF patients and the prog-
nostic impact of these parameters in AHF patients may be
driven by PV-independent factors. Direct measurements of
PV, as performed in this study, may provide a more accurate
assessment of the response of intravascular volume status to
decongestive therapy.
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Figure S1. Schematic model of volume distribution in intra-
vascular space and its changes (A) underlying Strauss formula
(B, C).
Figure S2. Agreement between estimated PV by
Kaplan-Hakim formula (ePVKaplan-Hakim) and absolute mea-
sured PV (mPV) upon enrollment (day 1). “Difference” indi-
cates difference between ePVKaplan-Hakim and mPV.
“Average” shows average of ePVKaplan-Hakim and mPV. Solid
line shows zero. Dotted lines show bias and bias ± 1.96 stan-
dard deviation. Data are presented in milliliters.
Figure S3. Absolute 48 h changes of mPV (milliliters) and bo-
dyweight (grams) are shown in individual patients. Patients
with decreasing PV are presented on the left, patients with
increasing PV on the right.
Figure S4. Agreement between estimated PV change by
Kaplan-Hakim (Δ%ePVKaplan-Hakim)(A) and Strauss’ formula
(Δ%ePVStrauss) (B) and measured PV change (Δ%mPV)
“Difference” indicates difference between Δ%ePV and
Δ%mPV change. “Average” shows average of Δ%ePV and
Δ%mPV. Solid line shows zero. Dotted lines show bias and
bias ± 1.96 standard deviation. Data are presented in
percentages.
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